501.0575 Weight-Loss Consumer Bill of Rights

(1) The Weight-Loss Consumer Bill of Rights shall consist of the following provisions:

(A) WARNING: RAPID WEIGHT LOSS MAY CAUSE SERIOUS HEALTH PROBLEMS. RAPID WEIGHT LOSS IS WEIGHT LOSS OF MORE THAN 11/2 POUNDS TO 2 POUNDS PER WEEK OR WEIGHT LOSS OF MORE THAN 1 PERCENT OF BODY WEIGHT PER WEEK AFTER THE SECOND WEEK OF PARTICIPATION IN A WEIGHT-LOSS PROGRAM.

(B) CONSULT YOUR PERSONAL PHYSICIAN BEFORE STARTING ANY WEIGHT-LOSS PROGRAM.

(C) ONLY PERMANENT LIFESTYLE CHANGES, SUCH AS MAKING HEALTHFUL FOOD CHOICES AND INCREASING PHYSICAL ACTIVITY, PROMOTE LONG-TERM WEIGHT LOSS.

(D) QUALIFICATIONS OF THIS PROVIDER ARE AVAILABLE UPON REQUEST.

(E) YOU HAVE A RIGHT TO:

ASK QUESTIONS ABOUT THE POTENTIAL HEALTH RISKS OF THIS PROGRAM AND ITS NUTRITIONAL CONTENT, PSYCHOLOGICAL SUPPORT, AND EDUCATIONAL COMPONENTS.
RECEIVE AN ITEMIZED STATEMENT OF THE ACTUAL OR ESTIMATED PRICE OF THE WEIGHT-LOSS PROGRAM, INCLUDING EXTRA PRODUCTS, SERVICES, SUPPLEMENTS, EXAMINATIONS, AND LABORATORY TESTS.
KNOW THE ACTUAL OR ESTIMATED DURATION OF THE PROGRAM.
KNOW THE NAME, ADDRESS, AND QUALIFICATIONS OF THE DIETITIAN OR NUTRITIONIST WHO HAS REVIEWED AND APPROVED THE WEIGHT-LOSS PROGRAM ACCORDING TO s. 468.505(1)(j), FLORIDA STATUTES.

(2) The copies of the Weight-Loss Consumer Bill of Rights to be posted according to s. 501.0573(6) shall be printed in at least 24-point boldfaced type on one side of a sign. The palm-sized copies to be distributed according to s. 501.0573(5) shall be in boldfaced type and legible. Each weight-loss provider shall be responsible for producing and printing appropriate copies of the Weight-Loss Consumer Bill of Rights.History.—s. 4, ch. 93-274; s. 45, ch. 2000-154.https://www.flsenate.gov/Laws/Statutes/2015/501.0575

RIVO guarantee

Free, expedited delivery

Doctor-led plans & coaching

No hidden fees

hello@rivohealth.co

1 (800) 705-8140

1309 Coffeen Avenue STE 1200

Sheridan Wyoming 82801

*The assessment made available on the RIVO website does not create a doctor-patient relationship between the individual completing the assessment and RIVO.

OpenLoop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to

determine if an individual does not qualify for GLP-1s. The answers an individual provides to the RIVO assessment consequently determine if the individual is screened

out of eligibility for GLP-1 medication, and an OpenLoop Health clinician will meet with an individual after checkout to determine if they qualify for a prescription.

OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and

consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from

compounded medications found on the RIVO platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations.

Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for

safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and

medical history.

We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of

compounded medication. RIVO does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the

website.

*The assessment made available on the RIVO website does not create a doctor-patient relationship between the individual completing the assessment and RIVO. OpenLoop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the RIVO assessment consequently determine if the individual is screened out of eligibility for GLP-1 medication, and an OpenLoop Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients. All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from compounded medications found on the RIVO platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and medical history. We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. RIVO does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers

We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies

to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

Pharmacy Providers

We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a

reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone.

RIVO patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using

medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4

mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. RIVO patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

Medication is included in the cost of the RIVO Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be

prescribed for weight loss. The trademarks, service marks, trade names (Wegovy® ,Ozempic®), and products displayed on this Internet site are protected and belong to

their respetive owners. Medical treatment is provided by “CareGLP Affiliated P.C.s,” and OpenLoop Health, affiliated networks for medical professional corporations and

associations. No data, photos, claims or any other information is associated with results derived from clinical trials, studies or public information and is always representative

of RIVO patient experience.

Medication is included in the cost of the RIVO Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy® ,Ozempic®), and products displayed on this Internet site are protected and belong to their respetive owners. Medical treatment is provided by “CareGLP Affiliated P.C.s,” and OpenLoop Health, affiliated networks for medical professional corporations and associations. No data, photos, claims or any other information is associated with results derived from clinical trials, studies or public information and is always representative of RIVO patient experience.

Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or

warranty is made regarding the accuracy, completeness, or reliability of such content. Individuals appearing in advertisements may be actors or AI portraying doctors and

are not licensed medical professionals.

Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content. Individuals appearing in advertisements may be actors or AI portraying doctors and are not licensed medical professionals.

Testimonials on the website are from RIVO patients. For patient privacy, images representing those testimonials may use models or AI.

Terms & Conditions

Privacy Practices

Refund Policy

Medical Consent

For California Residents